MongoDB R&D increased by 7.1% to $189.13M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 25.7%, from $150.40M to $189.13M. Over 4 years (FY 2022 to FY 2026), R&D shows an upward trend with a 23.4% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $64.75M | $72.40M | $82.26M | $89.42M | $96.37M | $108.04M | $106.39M | $110.89M | $116.82M | $125.42M | $128.15M | $145.55M | $146.06M | $148.97M | $151.41M | $150.40M | $168.83M | $181.74M | $176.61M | $189.13M |
| QoQ Change | — | +11.8% | +13.6% | +8.7% | +7.8% | +12.1% | -1.5% | +4.2% | +5.3% | +7.4% | +2.2% | +13.6% | +0.3% | +2.0% | +1.6% | -0.7% | +12.3% | +7.6% | -2.8% | +7.1% |
| YoY Change | — | — | — | — | +48.8% | +49.2% | +29.3% | +24.0% | +21.2% | +16.1% | +20.5% | +31.3% | +25.0% | +18.8% | +18.2% | +3.3% | +15.6% | +22.0% | +16.6% | +25.7% |